A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial

Journal of Urology

Volumn 185, Issue 1, 2011, Pages 121-125

  Wolters, Tineke ^a   Roobol, Monique J ^a   Van Leeuwen, Pim J ^a   Van Den Bergh, Roderick C N ^a   Hoedemaeker, Robert F ^b   Van Leenders, Geert J L H ^a   Schrder, Fritz H ^a   Van Der Kwast, Theodorus H ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SINT FRANCISCUS GASTHUIS   (Netherlands)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Early detection of cancer; Prostatic neoplasms; Tumor burden

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CALCULATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TRANSRECTAL ULTRASONOGRAPHY; TUMOR VOLUME;

AGED; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78649998755     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.08.082     Document Type: Article

References (20)

1. C. Gosselaar, M.J. Roobol, and F.H. Schrder Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int 95 2005 231
2. C.H. Bangma, R. Roemeling, and F.H. Schrder Overdiagnosis and overtreatment of early detected prostate cancer World J Urol 25 2007 3
3. J.I. Epstein, P.C. Walsh, and M. Carmicheal Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368
4. M. Han, A.W. Partin, and C.R. Pound Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy The 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555
5. P. Kupelian, J. Katcher, and H. Levin Correlation of clinical and pathological factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer Urology 48 1996 249
6. T.A. Stamey, F.S. Freiha, and J.E. McNeal Localized prostate cancer Relationship of tumor volume to clinical significance for treatment of prostate cancer Cancer 71 1993 933
7. T.A. Stamey More information on prostate specific antigen and prostate cancer J Urol 170 2003 457
8. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969
9. R.F. Hoedemaeker, E.T.G. Ruijter, J.A. Ruizeveld-de Winter The BIOMED II MPC study group Processing radical prostatectomy specimens A comprehensive and standardized protocol J Urol Pathol 9 1998 211
10. R.F. Hoedemaeker, J.B. Rietbergen, and R. Kranse Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer World J Urol 15 1997 339
11. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868
12. G. Draisma, R. Etzioni, and A. Tsodikov Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context J Natl Cancer Inst 101 2009 374
13. T.A. Stamey, J.E. McNeal, and C.M. Yemoto Biological determinants of cancer progression in men with prostate cancer JAMA 215 1999 1395
14. J.E. McNeal, D.G. Bostwick, and R.A. Kindrachuk Patterns of progression in prostate cancer Lancet 1 1986 60
15. R.T. Vollmer Percentage of tumor in prostatectomy specimens Am J Clin Pathol 131 2009 86
16. S. Sengupta, M.L. Blute, and S.M. Bagniewski After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer BJU Int 101 2008 170
17. M.M. Merrill, B.R. Lane, and A.M. Reuther Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer Urology 70 2007 294
18. E. Kikuchi, P.T. Scardino, and T.M. Wheeler Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 172 2004 508
19. S.P. Porten, M.R. Cooperberg, and P.R. Carroll The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease BJU Int 105 2010 472
20. T. Wolters, M.J. Roobol, and P. van Leeuwen Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer Eur Urol 2009 Epub ahead of print